Pfirzer and Merck Receive Key Regulatory Approvals

Now watching

Next video starts in : 7 Play

Pfirzer and Merck Receive Key Regulatory Approvals

Pfirzer and Merck Receive Key Regulatory Approvals
Replay video
Up next

What to Watch Wednesday: Netflix Takes Earnings Spotlight

Unlock your personal NFL Now stream by signing in to

Pfirzer and Merck Receive Key Regulatory Approvals

by TheStreet 1:22 mins

Pfirzer and Merck Receive Key Regulatory Approvals

by TheStreet 1:22 mins

Shares of Pfizer and Merck are in the spotlight on Wednesday after both companies won some key federal regulatory approvals. Pfizer received the backing of the Centers for Disease Control and Prevention's Advisory Committee on Immunization Practices. The group gave Pfizer's Prevnar 13 vaccine approval for people ages 65 and older. Also, watch shares of Merck after it received approval to sell Belsomra, its treatment for insomnia. It's a new type of drug considered to have fewer side effects than older medications such as Ambien. The FDA cleared the sleeping pill in lower doses than what Merck had originally sought. Now, the DEA must determine restrictions on prescribing the medication before it can hit the market. Merck expects to start selling Belsomra late this year or early in 2015. TheStreet's Ruben Ramirez has details from New York.



  1. 14:29

    Twitter lays off 8% of workforce and JPMorgan says no to free phones

  2. 2:49

    Where Clinton and Sanders stand on top economic issues

  3. 2:22

    US stocks are mixed as investors assess earnings, deals

  4. 2:32

    Twitter is laying off 8% of its global workforce

  5. 2:42

    No free Blackberry for some J.P. Morgan employees: WSJ

  6. 2:24

    How big of a problem is high-frequency trading?


  1. 0:49

    This rally deserves respect, but Nasdaq weakness glares

  2. 1:11

    Hard-to-please bond investors hold the key for stocks

  3. 4:04

    3 charts that show why stocks, oil, & emerging markets could rally by year-end

  4. 5:04

    Former Schwab CEO on the secret to his comeback, and the challenge of China

  5. 4:23

    Surprise! Paying CEOs for stock performance doesn't help companies: Cornell

  6. 1:08

    Stock investors forced to pause at yield signs

Market Movers

  1. 2:56

    bud stuff

  2. 12:29

    Bud, SABMiller strike deal; Big earnings in focus; Playboy covers up

  3. 2:56

    AB InBev, SABMiller brew up $100 billion deal

  4. 1:46

    Pepsi, Coca-Cola competing for investment in Chobani

  5. 2:13

    Playboy magazine to end publishing fully nude female photos

  6. 2:10

    Bud/Miller beer combo; J&J mixed results; FMC cuts outlook